Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BioCorRx Inc.

Get SEC filing alerts via email and in your feed for BioCorRx Inc.

BICX

BioCorRx Inc.

About BioCorRx Inc.

BioCorRx Inc. develops and provides addiction treatment solutions focused on substance use disorders, including alcoholism and opioid addiction. Its core offerings include the BioCorRx® Recovery Program, combining cognitive behavioral therapy and medication-assisted treatment, and the UnCraveRx® Weight Loss Program. Through its subsidiary BioCorRx Pharmaceuticals, the company develops implantable naltrexone pellets for long-acting treatment. It serves healthcare providers and patients, leveraging proprietary therapies and pharmaceutical innovations in addiction and weight management.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BioCorRx Inc.

1
1
BioCorRx Inc. BioCorRx Reports 59% Revenue Growth but Faces Increased Net Loss in Q1 2026

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
BioCorRx Inc. BioCorRx Reports 10,301.1% Revenue Growth to $797,244 in 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
BioCorRx Inc. BioCorRx Reports Revenue Growth to $635,224 and Decreased Net Loss in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BioCorRx Inc. BioCorRx Reports Revenue Surge to $178K but Faces $1.4M Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BioCorRx Inc. BioCorRx Reports 3,627% Revenue Increase to $134,899 in Latest 10-Q Filing

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BioCorRx Inc. BioCorRx Inc. Reports 91% Revenue Decline and Increased Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
BioCorRx Inc. BioCorRx Reports Significant Financial Challenges, No Revenue in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments